Skip to main content

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

IMA new masthead1

Internal Medicine Alert – March 15, 2012

March 15, 2012

View Archives Issues

  • Aspirin for Everyone?

    Aspirin can reduce the risk of nonfatal myocardial infarction, but not mortality, in people without coronary vascular disease, at the expense of increased risk of bleeding. It should not be routinely recommended.
  • Long-term Safety of Statins

    There do not appear to be any safety issues with the long-term use of statins.
  • Postoperative Complications in Patients with Obstructive Sleep Apnea

    More than half of patients undergoing non-cardiac surgery and polysomnography had obstructive sleep apnea, which was associated with an increased risk of perioperative complications, including hypoxemia, ICU transfer, and prolonged length of stay.
  • Exenatide Extended- Release for Injection (Bydureon™)

    The FDA has approved a once-weekly treatment for type 2 diabetes. The new product is a subcutaneously administered extended-release form of the glucagon-like peptide-1 receptor agonist, exenatide. Exenatide extended-release is marketed by Amylin Pharmaceuticals and Alkermes PLC as Bydureon.
  • Clinical Briefs By Louis Kuritzky, MD

    Zinc deficiency is defined as a serum zinc level < 60 mg/dL. Unfortunately, there is some question about the reliability of zinc levels to accurately reflect zinc status, since some persons with prototypic symptoms of zinc deficiency (loss of appetite, diarrhea, hair loss, delayed wound healing, and smell and taste disturbances) have normal zinc levels.
  • ECG Review: A Helpful Hand from aVR

    The 12-lead ECG shown above was obtained from a patient with new-onset chest pain. Where is the acute lesion likely to be?